Scarica l'app Stockscreener
3.11
2.96%
-0.10
Dopo l'orario di chiusura:
3.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.21
Aprire:
$3.185
Volume 24 ore:
1.27M
Relative Volume:
0.53
Capitalizzazione di mercato:
$339.59M
Reddito:
-
Utile/perdita netta:
$-209.38M
Rapporto P/E:
-1.6571
EPS:
-1.8768
Flusso di cassa netto:
$-179.81M
1 W Prestazione:
-2.35%
1M Prestazione:
-8.92%
6M Prestazione:
-10.49%
1 anno Prestazione:
+2.13%
Intervallo 1D:
$3.05
$3.21
Intervallo di 1 settimana:
$3.034
$3.40
Portata 52W:
$2.53
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.11 | 354.88M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-08-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-30 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Downgrade | Needham | Buy → Hold |
| 2025-05-27 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-30 | Iniziato | Wedbush | Outperform |
| 2024-12-18 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RCKT|Rocket Pharmaceuticals Inc|Price:3.240|Chg%:+0.050 - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
If You Invested $1,000 in Rocket Pharmaceu (RCKT) - Stock Titan
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - The National Law Review
Rocket Pharmaceuticals, Inc. Revenue Breakdown – MUN:9IP1 - TradingView
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a Potential 186% Upside in Genetic Therapy Innovation - DirectorsTalk Interviews
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Frontier tech research, news & data - MLQ.ai
Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends - Ad-hoc-news.de
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks - TradingView
Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1 - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake - Stock Titan
Price to earnings forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - AOL.com
Form 144 ROCKET PHARMACEUTICALS For: 7 July By Investing.com - Investing.com South Africa
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Director at Rocket Pharmaceuticals (RCKT) receives RSUs and stock options - Stock Titan
Rocket Pharmaceuticals (RCKT) director receives new RSU and stock option awards - Stock Titan
Price to book forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Equity awards granted to RCKT director and 10% owner Roderick Wong - Stock Titan
Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - The National Law Review
Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings - TradingView
RCKT Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineHigh Estimate Range - dars.gov.et
Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer – SEC 8-K Filing June 2026 - Minichart
Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer - Stock Titan
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM: RCKT) added to Russell Microcap Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM: RCKT) added to Russell 3000E Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Join Class Action to Recover Losses from Rocket Pharmaceuticals - The National Law Review
RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Befor - The National Law Review
Rocket Pharmaceuticals, Inc. (RCKT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 11, 2025 - The National Law Review
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Price to earnings forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Price to sales forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Rocket Pharma updates cash position after selling priority review voucher - MSN
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rocket Pharmaceuticals Inc Azioni (RCKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
May 21 '26 |
Option Exercise |
1.69 |
76,490 |
129,345 |
1,117,408 |
| Shah Gaurav | CEO |
May 21 '26 |
Sale |
3.09 |
55,684 |
171,841 |
1,061,724 |
| Shah Gaurav | CEO |
May 19 '26 |
Sale |
3.01 |
2,409 |
7,261 |
1,040,918 |
| Wilson Martin | General Counsel |
May 19 '26 |
Sale |
3.01 |
662 |
1,995 |
677,977 |
| Militello John | See Remarks |
May 19 '26 |
Sale |
3.01 |
384 |
1,157 |
89,780 |
2.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):